Patents Examined by S. J. Friedman
  • Stabilized solutions of psychotropic agents
    Patent number: 5208261
    Abstract: Disclosed are stabilized aqueous preparations containing an antidepressant in admixture with a stabilizing compound such as L-methionine, D-methionine, DL-methionine, or mixtures thereof. The stabilized preparations display better stability when exposed to light, relatively high temperatures, time, and peroxides resulting in longer shelf-lives. Antidepressants which are stabilized include mirtazapine, mianserin, septiline, and amitriptyline.
    Type: Grant
    Filed: October 1, 1991
    Date of Patent: May 4, 1993
    Assignee: Akzo N.V.
    Inventors: Petrus J. M. Van Den Oetelaar, Maria M. F. Mentink
  • Pain controlling composition and method of preparation
    Patent number: 5206267
    Abstract: A composition, for producing pain relief in a body region, comprises a sterile, stable suspension of butyl aminobenzoate in a non-toxic, aqueous carrying medium in which the butyl aminobenzoate is substantially insoluble. The aqueous carrying medium consists essentially of water as the major constituent and a suspending agent composed of (a) polyethylene glycol and (b) a wetting agent for the butyl aminobenzoate, with a ratio of (a) to (b) in the range of about 50/1 to 125/1. The butyl aminobenzoate is milled to a particle size in the range of about 5 to 50 microns in the presence of the suspending agent.
    Type: Grant
    Filed: April 20, 1992
    Date of Patent: April 27, 1993
    Inventor: Morton Shulman
  • Method of treatment of Parkinsons's disease using phytic acid
    Patent number: 5206226
    Abstract: A method is provided for treating Parkinson's Disease by administering to a subject an effective symptom-alleviating amount of a compound selected from the group consisting of phytic acid, phytate salt, an isomer or hydrolysate of phytic acid or phytate salt, or a mixture of any combination thereof. The preferred method of administration is by oral dosages of about 1/8 to 1/2 grams/kilogram bodyweight per day.
    Type: Grant
    Filed: December 13, 1991
    Date of Patent: April 27, 1993
    Inventor: Robert Sabin
  • Cholecystokinin antagonists
    Patent number: 5206238
    Abstract: Compounds of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecycstokinin (CCK) and have properties useful for treating panic disorder and for directly inducing anlagesia.
    Type: Grant
    Filed: April 15, 1992
    Date of Patent: April 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Mark G. Bock, Roger M. Freidinger
  • Benzodiazepine analogs
    Patent number: 5206237
    Abstract: Pharmaceutical compositions containing benzodiazepines of the formula: ##STR1## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.
    Type: Grant
    Filed: May 14, 1991
    Date of Patent: April 27, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Mark G. Bock, Ben E. Evans
  • Treatment of organ transplantation rejection
    Patent number: 5204329
    Abstract: 4-Quinoline-carboxylic acid derivatives, such as 2-(2'-fluoro-1,1'-biphenyl-4-yl)-6-fluoro-3-methyl-4-quinoline carboxylic acid, in combination with other immunosuppressive agents are useful for the treatment and/or prevention of transplantation rejection, graft vs. host disease, autoimmune diseases, and chronic inflammatory disease.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: April 20, 1993
    Assignee: Du Pont Merck Pharmaceutical Company
    Inventors: Neil R. Ackerman, Bruce D. Jaffee
  • Treatment of anxiety
    Patent number: 5204356
    Abstract: The invention relates to the use of compounds which act as 5-hydroxytryptamine (5-HT) antagonists at 5-HT "M" receptors in the treatment of anxiety.
    Type: Grant
    Filed: January 29, 1992
    Date of Patent: April 20, 1993
    Assignee: Glaxo Group Limited
    Inventor: Michael B. Tyers
  • Furanone anti-inflammatory agents
    Patent number: 5202350
    Abstract: New compounds (3-alkyl-5-hydroxy-3,4-dihydrofuran-2-ones) of the following general structure: ##STR1## wherein R is an alkyl group or a phenylalkyl group with the alkyl moiety containing at least 6 carbon atoms, are disclosed as useful in inhibiting phospholipase A.sub.2.
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: April 13, 1993
    Assignee: Bristol-Myers Squibb Co.
    Inventors: F. Christopher Zusi, Suresh Marathe, William Somerville, Kenneth M. Tramposch
  • Agent for the TSH suppression and treatment of struma
    Patent number: 5200428
    Abstract: The agent for TSH suppression and for treatment of struma contains a therapeutically effective dose of 3,5-diiodo-L-thyronine and conventional galenic auxiliary materials.
    Type: Grant
    Filed: August 23, 1991
    Date of Patent: April 6, 1993
    Assignee: Henning Berlin GmbH
    Inventor: Claus Horst
  • Medicaments for the treatment of cerebral apoplexy
    Patent number: 5200410
    Abstract: A method of treating cerebral apoplexy in a patient in need thereof which comprises administering to said patient an amount effective therefor of a serotonin agonist which has a binding strength of less than 10,000 nmol/l on binding to 5HT.sub.1A receptors.
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: April 6, 1993
    Assignee: Troponwerke GmbH & Co.
    Inventors: Jorg Traber, Gerhard-Wilhelm Bielenberg
  • Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents
    Patent number: 5198459
    Abstract: The invention provides use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent.
    Type: Grant
    Filed: June 6, 1991
    Date of Patent: March 30, 1993
    Assignee: Sandoz Ltd.
    Inventors: Assunta Imperato, Dietmar Romer
  • Medicaments
    Patent number: 5198447
    Abstract: The invention relates to the use of compounds which act as antagonists of 5-hydroxytryptamine (5-HT) at 5-HT.sub.3 receptors for the relief or prevention of a withdrawal syndrome resulting from addiction to a drug or substance of abuse and/or for the suppression of dependence on drugs or substances of abuse.
    Type: Grant
    Filed: July 16, 1991
    Date of Patent: March 30, 1993
    Assignee: Glaxo Group Limited
    Inventor: Michael B. Tyers
  • Dextromethorphan antitussive compositions
    Patent number: 5196436
    Abstract: The subject invention involves antitussive pharmaceutical compositions for the peroral administration of dextromethorphan, the composition being at a pH of from about 8 to about 11.
    Type: Grant
    Filed: February 24, 1992
    Date of Patent: March 23, 1993
    Assignee: The Procter & Gamble Company
    Inventor: Ronald L. Smith
  • Excitatory amino acid receptor antagonists in methods for the use thereof
    Patent number: 5196421
    Abstract: Excitatory amino acid receptor antagonists and methods for the use thereof are disclosed. The antagonists include compounds having the preferred formula: ##STR1## in which: each of A.sub.1, A.sub.2 and A.sub.3 is independently either C or N, except that at least one of A.sub.1, A.sub.2 and A.sub.3 is N; one of A.sub.4 and A.sub.5 is C and the other is N; each R.sub.1 and R.sub.2 is independently hydrogen, halogen, CN, NO.sub.2, alkyl, aromatic, azido or CF.sub.3 ; and R.sub.3 is hydrogen, alkyl, aromatic or CF.sub.3. Also included are the tautomers thereof, and the pharmaceutically acceptable salts of (III) and (IV) and the tautomers thereof. These compounds are useful as EAA antagonists for blocking one or more EAA receptors, as neuroprotective agents, and in the treatment of various neurological disorders associated with EAA receptors.
    Type: Grant
    Filed: June 25, 1992
    Date of Patent: March 23, 1993
    Assignee: Eli Lilly and Company
    Inventors: Loretta A. McQuaid, Charles H. Mitch, Paul L. Ornstein, Darryle D. Schoepp, Edward C. R. Smith
  • Systemic anti-inflammatory treatment
    Patent number: 5194451
    Abstract: A method of arthritis and other inflammatory diseases in humans or other mammals, comprising introducing into the circulatory system of the human or other mammal to be treated a composition consisting essentially of at least one C-20 to C-26 aliphatic alcohol in a physiologically compatible carrier is disclosed.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: March 16, 1993
    Inventor: David H. Katz
  • Use of bridged tricyclic amine derivatives as anti-ischemic agents
    Patent number: 5192762
    Abstract: Certain bridged tricyclic amine compounds are described as being therapeutically effective in treatment of CNS disorders resulting from neurotoxic damage or neurodegenerative diseases, particularly those CNS disorders resulting from ischemic events. Compounds of particular interest for use as neuroprotective agents are those of the formula ##STR1## wherein each of R.sup.1 and R.sup.2 is independently selected from hydrido, loweralkyl, benzyl and phenyl; wherein each of R.sup.1 through R.sup.7 is independently selected from hydrido, loweralkyl, hydroxy, benzyl, phenyl, loweralkoxy, phenoxy, benzyloxy, halo and haloloweralkyl; wherein R.sup.
    Type: Grant
    Filed: August 14, 1991
    Date of Patent: March 9, 1993
    Inventors: Nancy M. Gray, Patricia C. Contreras
  • Methods using antiallergics and antihistamines
    Patent number: 5192780
    Abstract: Compositions of an antiallergic compound and an antihistamine for preventing and treating ophthalmic allergic responses are disclosed. Methods for preventing and treating ophthalmic allergic responses with the compositions are also disclosed.
    Type: Grant
    Filed: July 23, 1991
    Date of Patent: March 9, 1993
    Assignee: Alcon Laboratories, Inc.
    Inventors: Billie M. York, Stella M. Robertson, John M. Yanni
  • Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
    Patent number: 5190970
    Abstract: A method is provided for preventing or reducing the risk of or treating Type II diabetes by administering a cholesterol lowering drug, such as pravastatin, alone or in combintion with an ACE inhibitor, such as captopril, zofenopril, ceranapril, fosinopril, enalapril or lisinopril.
    Type: Grant
    Filed: December 20, 1991
    Date of Patent: March 2, 1993
    Assignee: E. R. Squibb & Sons, Inc.
    Inventors: Henry Y. Pan, Michael Bergman
  • Method of stimulating superoxide generation
    Patent number: 5189038
    Abstract: The present invention is directed to a method of stimulating superoxide generation using phenolic thioethers which stimulate the generation of superoxide.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: February 23, 1993
    Assignee: G. D. Searle and Co.
    Inventors: Richard A. Mueller, Akira Nakao, Richard A. Partis
  • Treatment of cocaine addiction
    Patent number: 5189064
    Abstract: Cocaine addiction is treated by administration of an endorphinase or enkephalinase inhibitor, and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalin releaser. These components promote restoration of normal neurotransmitter function and are non-addictive. Use of the dopamine precursors L-phenylalanine or L-tyrosine, the enkephalinase inhibitor D-phenylalanine and/or the serotonin precursor L-tryptophan is especially preferred.
    Type: Grant
    Filed: May 14, 1990
    Date of Patent: February 23, 1993
    Assignee: Matrix Technologies, Inc.
    Inventors: Kenneth Blum, Michael C. Trachtenberg